DNA Plasmid Manufacturing
Inovio has controlling ownership in VGX International, a Korea-based publicly traded company (Korean Stock Exchange: Stock Ticker Number 011000). In 2008, VGX Pharmaceuticals (which merged with Inovio on June 1, 2009) sold its substantial assets in DNA plasmid manufacturing, consisting of expertise and manufacturing facilities to produce DNA vaccines, to VGX International's US subsidiary, VGXI, Inc.
VGXI, Inc. is a leading contract manufacturer of DNA plasmid products. The company's cGMP and non-cGMP products have passed rigorous international regulatory reviews. VGXI's patented manufacturing process and cGMP production facilities, along with the company's flexibility, experience, reliability and value, provide the ability to satisfy unique requirements.